COVID-19 Vaccine and Cancer: What the Evidence Shows

COVID-19 vaccines are recommended for people with cancer, including those on active treatment. Major oncology organizations worldwide have endorsed vaccination for this group, and the evidence accumulated since 2021 consistently shows that the vaccines are safe and effective at reducing severe illness and death from COVID-19 in most cancer patients. The picture has some real wrinkles, though: certain cancer types and treatments significantly weaken the immune response to vaccination, and a recent large observational study has raised questions about cancer incidence after vaccination that deserve honest scrutiny rather than dismissal.

Vaccine Effectiveness in People With Solid Tumors

For the largest group of cancer patients, those with solid tumors like breast, lung, or colorectal cancer, the vaccines work well. A prospective trial published in The Lancet Oncology tested the Moderna mRNA vaccine in patients receiving chemotherapy, immunotherapy, or a combination. After two doses, virtually all participants mounted measurable antibody responses. Patients on immunotherapy alone hit 100% seroconversion, and even patients on chemotherapy reached 97% or higher, compared to 100% in healthy controls.¹ Those numbers are reassuring. While the antibody levels in treated patients were somewhat lower than in healthy people, the vast majority cleared the threshold considered protective.

This does not mean every solid-tumor patient responds identically. Patients with more aggressive chemotherapy regimens, those who are severely malnourished, or those who received their vaccine dose at the lowest point of their white-blood-cell cycle sometimes mount weaker responses. But as a group, people with solid tumors are among the cancer patients for whom vaccination works closest to normal.

Blood Cancers Tell a Different Story

Patients with blood cancers, such as lymphoma, leukemia, and myeloma, face a much harder road. A systematic review and meta-analysis pooling data from multiple studies found that these patients were substantially less likely to develop an antibody response compared to people with solid tumors or healthy individuals. After full immunization, patients with blood cancers had roughly 62% of the antibody response rate seen in healthy subjects and about 73% of the rate seen in solid-tumor patients.² That gap is significant. It means a meaningful minority of blood-cancer patients finish their vaccine series without the robust protection most people get.

The reason is built into the disease. Blood cancers directly attack or crowd out the immune cells responsible for responding to a vaccine. Leukemias can deplete healthy white blood cells. Myelomas corrupt the antibody-producing plasma cells. Lymphomas disrupt the lymph nodes where immune responses are coordinated. When the very machinery a vaccine relies on is damaged by the cancer itself, even a well-designed vaccine has less to work with.

This does not mean vaccination is pointless for these patients. Even a partial immune response offers some protection, and T-cell responses (which are harder to measure in routine blood tests) may still provide a layer of defense against severe illness. But it does mean that blood-cancer patients should not assume they are as protected as someone without cancer after the same number of doses.

When Specific Treatments Blunt the Response

Beyond the cancer itself, certain treatments used against blood cancers can further erode vaccine effectiveness. The clearest example is anti-CD20 therapy, a class of drugs including rituximab that is widely used to treat lymphomas and some autoimmune conditions. These drugs work by wiping out B cells, which are the immune cells responsible for producing antibodies. That is exactly what they are supposed to do for the disease, but it also means the patient’s body has very few B cells available to respond when a vaccine shows up.

A study published in Frontiers in Immunology tracked lymphoma patients receiving anti-CD20 treatment and found that both short-term and long-term production of antibodies against the COVID-19 spike protein were reduced compared to healthy controls.³ Some patients produced no detectable antibodies at all, even after multiple vaccine doses. The effect can persist for months after the last rituximab infusion, because B cells take time to recover.

Anti-CD20 therapy is not the only treatment that weakens the response. High-dose corticosteroids, certain targeted therapies like BTK inhibitors used in chronic lymphocytic leukemia, and stem cell transplants all suppress the immune system in ways that can reduce vaccine effectiveness. The common thread is that any treatment which depletes or suppresses the specific immune cells needed to respond to a vaccine will reduce the protection that vaccine can provide.

Protection Against Severe COVID-19 in Cancer Patients

Even when the antibody response is imperfect, vaccination provides a real and measurable shield against the worst outcomes. A large U.S. study published in JAMA Oncology looked at vaccinated cancer patients who experienced breakthrough COVID-19 infections between late 2020 and November 2021. Among those with breakthrough infections, the hospitalization rate was about 32% and the mortality rate was roughly 4%. Those numbers sound concerning on their own, but the comparison is what matters: unvaccinated cancer patients who caught COVID-19 fared far worse.⁴

Cancer patients are already at higher risk from COVID-19 than the general population. Their immune systems are compromised by the disease, by treatment, or by both. Severe COVID-19 can also force delays or changes to cancer treatment, which can affect cancer outcomes. Vaccination reduces the chance of that cascade happening. For patients on active treatment, avoiding a severe COVID-19 infection is not just about surviving the virus; it is about keeping their cancer treatment on track.

When to Get Vaccinated Around Treatment

Timing matters. The major oncology organizations, including the European Society for Medical Oncology, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer, all support vaccination in cancer patients receiving active therapy.⁵ But within that broad endorsement, the details of timing can influence how well the vaccine works.

For patients on standard chemotherapy, vaccination is generally recommended between cycles, ideally timed so the immune system is not at its lowest point. Many oncologists aim for a window a few days before the next chemotherapy cycle, when white blood cell counts have had time to recover. For patients about to start anti-CD20 therapy, getting vaccinated before starting treatment gives the best chance of a full response, since B cells are still present. If anti-CD20 therapy has already begun, waiting at least six months after the last dose before vaccinating can improve the odds of a response, though this is not always practical.

Patients who have undergone stem cell transplants or CAR-T cell therapy present a special case. Their immune systems are essentially rebuilt from scratch, and vaccination too early after the procedure may produce no response at all. Guidelines generally recommend waiting at least three months after a stem cell transplant, though some centers prefer to wait longer depending on the patient’s immune recovery. The overarching principle is that vaccination sooner is almost always better than skipping it entirely, even if the response is likely to be weaker than ideal.

The South Korean Study and Cancer Incidence Questions

A large population-based cohort study from South Korea, published in 2025, grabbed attention because it reported statistically higher rates of several new cancer diagnoses in vaccinated people within the first year after vaccination. The study found elevated hazard ratios for thyroid, gastric, colorectal, lung, breast, and prostate cancers among the vaccinated group compared to unvaccinated controls.⁶ The numbers were not trivial: the hazard ratio for prostate cancer was about 1.69, meaning vaccinated men were diagnosed with prostate cancer at roughly 69% higher rates, and lung cancer showed a hazard ratio of around 1.53.

These findings need careful context before drawing conclusions. This was an observational study, not a randomized trial. It compared people who chose to get vaccinated with people who did not. Those two groups differ in many ways beyond vaccination status. People who get vaccinated tend to engage more with the healthcare system. They visit doctors, get screenings, and receive diagnoses that might otherwise be delayed or missed in people who avoid medical care. This is a well-known phenomenon in epidemiology called detection bias, and it is especially relevant for cancers like thyroid and prostate cancer, where screening can uncover slow-growing tumors that would not have been found otherwise.

The study also used a one-year follow-up window. Cancer takes years to develop from a single mutated cell to a diagnosable tumor. If vaccines were somehow causing cancer at a cellular level, you would not expect to see a spike in fully formed, diagnosable tumors within 12 months. What you would expect to see is exactly what detection bias produces: more diagnoses in the group with more medical contact. The authors themselves acknowledged these limitations. They did not claim to prove that vaccination causes cancer, and the study’s design cannot establish that kind of causal link.

That said, dismissing the study out of hand is not the right response either. Large observational signals deserve follow-up, and responsible researchers are tracking long-term cancer outcomes in vaccinated populations worldwide. The honest answer right now is that no biological mechanism has been identified by which mRNA or other COVID-19 vaccines would initiate cancer, and randomized controlled trial data from the vaccine approval process did not show any cancer signal. But long-term surveillance continues, and that is exactly how safety monitoring is supposed to work.

Do COVID-19 Vaccines Affect Existing Tumors

A separate question from whether vaccines cause new cancers is whether they affect cancers that already exist. There were scattered case reports early in the pandemic of lymph nodes near the vaccination site swelling and showing up on imaging scans, sometimes mimicking cancer spread. This caused anxiety for patients undergoing cancer surveillance, because enlarged lymph nodes on a PET scan or CT can look like metastatic disease. Oncologists quickly learned to account for this: reactive lymph node swelling after vaccination is a normal immune response, not a sign of cancer progression. Most major radiology and oncology societies issued guidance recommending that imaging be timed to avoid the window right after vaccination, or that radiologists note recent vaccination when interpreting scans.

More intriguing are occasional reports of tumor regression after vaccination, where a patient’s existing cancer appeared to shrink following a COVID-19 vaccine dose. These are anecdotal and rare, and the mechanism is speculative. One hypothesis is that the strong immune activation triggered by the vaccine can sometimes wake up the immune system’s ability to recognize tumor cells as well. This is conceptually related to how cancer immunotherapy works, priming the immune system to fight the body’s own abnormal cells. But anecdotes are not evidence of a treatment effect, and no one should view COVID-19 vaccination as a cancer therapy.

mRNA Vaccine Technology and Cancer Treatment Research

The mRNA platform used in the Pfizer-BioNTech and Moderna COVID-19 vaccines was not developed solely for infectious diseases. BioNTech, the company behind the Pfizer vaccine, was originally founded to develop mRNA-based cancer therapies. The idea is that you can design an mRNA sequence encoding proteins found on a patient’s specific tumor, inject it, and teach the immune system to attack cells displaying those proteins. This is personalized cancer vaccination, using the same lipid-nanoparticle delivery system that delivered billions of COVID-19 vaccine doses.

Clinical trials of personalized mRNA cancer vaccines are underway for melanoma, pancreatic cancer, and several other tumor types. Early-phase results have been encouraging enough that major pharmaceutical partnerships have formed around the technology. The experience gained from mass-producing and administering mRNA COVID-19 vaccines has accelerated this research considerably, both by proving that the platform works at scale and by generating real-world safety data on mRNA delivery in hundreds of millions of people. For cancer patients and their families, this is one of the more hopeful developments to emerge from the pandemic-era investment in mRNA science.

Practical Steps for Cancer Patients

If you are being treated for cancer or have recently finished treatment, the practical takeaways from the evidence are straightforward. Talk to your oncologist about timing rather than skipping vaccination altogether. If you are on a treatment known to suppress B cells, like rituximab, ask whether getting vaccinated before starting therapy is feasible, or whether waiting for a recovery window makes sense. If you have already been vaccinated and are on immunosuppressive treatment, ask about additional booster doses, since many guidelines now recommend extra doses for immunocompromised individuals.

Household contacts matter too. If your own immune response to the vaccine is likely to be weak, the people around you being vaccinated provides an additional buffer. This is not a substitute for your own vaccination, but it reduces the chance of COVID-19 entering your household in the first place. For patients who produce no antibodies after vaccination, some clinicians have discussed pre-exposure prophylaxis with monoclonal antibodies as an additional protective measure, though the availability and effectiveness of these products has shifted as new variants have emerged.

Concerns about the South Korean data or similar reports are understandable, and bringing them up with your oncologist is perfectly reasonable. The current weight of evidence, including large randomized trials, real-world effectiveness studies, and recommendations from every major oncology society, supports vaccination. But asking questions and staying informed about ongoing safety surveillance is not the same as being anti-vaccine. It is being a good patient.